针对 SARS-CoV-2 的当前疗法的体外数据。
In Vitro Data of Current Therapies for SARS-CoV-2.
机构信息
First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
出版信息
Curr Med Chem. 2020;27(27):4542-4548. doi: 10.2174/0929867327666200513075430.
BACKGROUND
In December 2019, a new coronavirus, named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), emerged from China, causing pneumonia outbreaks first in the Wuhan region and then spread worldwide. Due to a lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the most efficient tool to find a therapeutic solution.
OBJECTIVES
The aim of this study was to summarize in vitro data of current agents used for the management of SARS-CoV-2 all over the world.
METHODS
A literature search of articles from January 2000 until April 2020 was performed using MEDLINE, EMBASE and the Cochrane Library to assess in vitro data of current or putative therapies for SARS-CoV-2.
RESULTS
Although in vitro studies are scarce, data regarding chloroquine, hydroxychloroquine, remdesivir, nitazoxanide, teicoplanin, ivermectin, lopinavir, homoharringtonine, and emetine seem promising.
CONCLUSION
Scientists all over the world should work together and increase their efforts in order to find feasible and efficient solutions against this new global viral threat.
背景
2019 年 12 月，一种新型冠状病毒，命名为严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2），起源于中国，首先在武汉地区引发肺炎疫情，随后在全球范围内蔓延。由于缺乏有效和特效的治疗方法，需要控制疫情，药物再利用似乎是寻找治疗方法的最有效工具。
目的
本研究旨在总结目前全球用于管理 SARS-CoV-2 的药物的体外数据。
方法
使用 MEDLINE、EMBASE 和 Cochrane 图书馆对 2000 年 1 月至 2020 年 4 月的文章进行文献检索，以评估目前或潜在的 SARS-CoV-2 治疗方法的体外数据。
结果
尽管体外研究较少，但氯喹、羟氯喹、瑞德西韦、硝唑尼特、替考拉宁、伊维菌素、洛匹那韦、高三尖杉酯碱和依米丁的数据似乎很有希望。
结论
全世界的科学家应该共同努力，加大力度，寻找针对这一新的全球病毒威胁的可行和有效的解决方案。
Zotero 插件